secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2026-10-06T20:06:55+00:00
Accession:  0001193125-26-415555
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Inovio adds Delaware exclusive-forum bylaw covering derivative and fiduciary-duty suits
--------------------------------------------------------------------------------

- Board approved the Bylaws Amendment on October 6, 2026, effective immediately; CFO Peter Kies signed the report.
- New Article 12 designates the Delaware Court of Chancery as exclusive forum for derivative actions and claims of breach of fiduciary duty by directors, officers or stockholders.
- The U.S. federal district courts are named the exclusive forum for any complaint arising under the Securities Act of 1933.
- Full text of the amendment is filed as Exhibit 3.1 to the Form 8-K; no financial terms or dollar amounts disclosed.
- No change to the Company's certificate of incorporation, fiscal year, or share count was disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526415555/0001193125-26-415555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526415555/d127604d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-415555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer